Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CAO Sells 2,000 Shares of Stock

by · The Cerbat Gem

BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction on Monday, December 8th. The shares were sold at an average price of $74.26, for a total transaction of $148,520.00. Following the completion of the transaction, the chief accounting officer owned 130,297 shares in the company, valued at approximately $9,675,855.22. This represents a 1.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

BridgeBio Pharma Stock Down 0.2%

Shares of BBIO stock opened at $71.54 on Wednesday. BridgeBio Pharma, Inc. has a 52-week low of $25.34 and a 52-week high of $75.10. The stock’s 50-day moving average price is $62.85 and its 200 day moving average price is $51.96. The stock has a market capitalization of $13.79 billion, a PE ratio of -17.06 and a beta of 1.25.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.07). The firm had revenue of $120.70 million during the quarter, compared to analyst estimates of $107.71 million. BridgeBio Pharma’s revenue was up 4318.0% on a year-over-year basis. During the same period in the previous year, the business earned ($0.86) EPS. Analysts expect that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current fiscal year.

Institutional Trading of BridgeBio Pharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BBIO. Strs Ohio boosted its position in shares of BridgeBio Pharma by 1.1% in the third quarter. Strs Ohio now owns 18,600 shares of the company’s stock worth $966,000 after acquiring an additional 200 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of BridgeBio Pharma by 28.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,020 shares of the company’s stock worth $53,000 after buying an additional 227 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in BridgeBio Pharma by 22.3% during the second quarter. Steward Partners Investment Advisory LLC now owns 1,250 shares of the company’s stock valued at $54,000 after acquiring an additional 228 shares during the period. Gabelli Funds LLC grew its holdings in shares of BridgeBio Pharma by 0.3% during the 2nd quarter. Gabelli Funds LLC now owns 73,750 shares of the company’s stock worth $3,185,000 after purchasing an additional 250 shares during the period. Finally, First Bank & Trust raised its holdings in BridgeBio Pharma by 3.9% in the second quarter. First Bank & Trust now owns 8,822 shares of the company’s stock valued at $381,000 after buying an additional 329 shares during the period. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on BBIO shares. UBS Group raised their target price on BridgeBio Pharma from $72.00 to $82.00 and gave the company a “buy” rating in a report on Friday, September 12th. Raymond James Financial restated an “outperform” rating and set a $71.00 target price (up from $69.00) on shares of BridgeBio Pharma in a research report on Thursday, October 30th. The Goldman Sachs Group boosted their price target on BridgeBio Pharma from $55.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Truist Financial reaffirmed a “buy” rating and set a $80.00 price objective (up from $66.00) on shares of BridgeBio Pharma in a report on Thursday, October 30th. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 target price on shares of BridgeBio Pharma in a report on Monday, November 3rd. Twenty equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $74.37.

Check Out Our Latest Analysis on BridgeBio Pharma

BridgeBio Pharma Company Profile

(Get Free Report)

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

See Also